Biology subjects

Wolf, M. J.

Publications and source records attributed to Wolf, M. J..

8 recordsLinked to original sources

bioRxiv2026

Therapeutic targeting of MYBPC3 mutation-specific hypertrophic cardiomyopathy guided by network modeling

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death with genotype positive cases most commonly associated with mutations of cardiac myosin binding protein-C (MYBPC3). Recently approved drugs for HCM target the myofilaments rather than the aberrant molecular signaling pathways that drive long-term remodeling. Here, we identified a patient with familial HCM that was associated with a MYBPC3 W1078 truncation mutation. A CRISPR knock-in mouse model of the orthologous mutation MYBPC3 W1082 exhibited marked cardiac hypertrophy including wall thickening, reduced ejection fraction, and decreased survival. To identify pathways, mechanisms, and potential candidate therapeutics, we integrated the MYBPC3 mutation into a computational network model of the signaling underlying familial cardiomyopathy. The network model predicted that the MYBPC3 mutation drove hypertrophy through mTOR/PI3K pathways, consistent with the results of RNA sequencing of cardiomyocytes of MYBPC3W1082*/W1082* mice. A virtual drug screen using FDA-approved drugs predicted that the mTOR inhibitor, Rapamycin, could mitigate mutation-induced hypertrophy. We then experimentally validated the effects of Rapamycin on hypertrophic responses using cultured cardiomyocytes. Further, Rapamycin attenuated cardiac hypertrophy and fibrosis of MYBPC3W1082*/W1082* mice in vivo. mTOR inhibitors (rapamycin and everolimus) were associated with a decreased incidence of cardiac hypertrophy associated diagnostic codes in patients in the FDA Adverse Events Reporting System. Query of electronic health records and echocardiograms from a University of Virginia cohort of patients treated with mTOR or calcineurin inhibitors showed that patients prescribed everolimus or tacrolimus had reduced LV wall thicknesses. Together, these studies suggest that targeting mTOR as a translationally relevant target for a mutation-induced hypertrophic cardiomyopathy, as well as demonstrating the utility of guiding precision therapies by iterating between network models and experimental validation.

physiology↗

bioRxiv2025

Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury

The adult mammalian heart has a limited ability to regenerate lost myocardium following myocardial infarction (MI), largely due to the poor proliferative capacity of cardiomyocytes (CMs). Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a known regulator of cell quiescence, though the mechanisms underlying its function remain unclear. Previous studies have shown that pharmacological inhibition of DYRK1A using harmine induces CM cell cycle re-entry after ischemia/reperfusion (I/R) MI. Here, we developed a computational network model of DYRK1A-mediated regulation of the cell cycle, which predicts how DYRK1A inhibition promotes CM re-entry. To validate these predictions, we tested selective DYRK1A inhibitors and observed robust induction of cell cycle activity in neonatal rat cardiomyocytes (NRCMs). Integrating our network model with bulk RNA-sequencing data from DYRK1A inhibitor-treated NRCMs, we identified E2F1 as a key transcriptional driver of cell cycle gene expression. Finally, we demonstrate that both pharmacological and post-developmental inhibition of DYRK1A enhances heart function and increases CM cycling following I/R MI. Our findings suggest that functional recovery induced by small molecule inhibitor of DYRK1A is mediated by the induction of cycling CMs. One Sentence SummaryInhibition of DYRK1A through LCTB-92 induces cardiomyocyte cycling and improved heart function in a mouse model of ischemic/reperfusion injury.

pharmacology and toxicology↗

bioRxiv2024

Logic-based machine learning predicts how escitalopram inhibits cardiomyocyte hypertrophy

IntroductionCardiomyocyte hypertrophy is a key clinical predictor of heart failure. High-throughput and AI-driven screens have potential to identify drugs and downstream pathways that modulate cardiomyocyte hypertrophy. MethodsHere we developed LogiRx, a logic-based mechanistic machine learning method that predicts drug-induced pathways. We applied LogiRx to discover how drugs discovered in a previous compound screen attenuate cardiomyocyte hypertrophy. We experimentally validated LogiRx predictions in neonatal cardiomyocytes, adult mice, and two patient databases. ResultsUsing LogiRx, we predicted anti-hypertrophic pathways for 7 drugs currently used to treat non-cardiac disease. We experimentally validated that escitalopram (Lexapro) and mifepristone inhibit hypertrophy of cultured cardiomyocytes in two contexts. The LogiRx model predicted that escitalopram prevents hypertrophy through an "off-target" serotonin receptor/PI3K{gamma} pathway, mechanistically validated using additional investigational drugs. Further, escitalopram reduced cardiomyocyte hypertrophy in a mouse model of hypertrophy and fibrosis. Finally, mining of both FDA and University of Virginia databases showed that patients with depression on escitalopram have a lower incidence of cardiac hypertrophy than those prescribed other serotonin reuptake inhibitors that do not target the serotonin receptor. ConclusionMechanistic machine learning by LogiRx discovers drug pathways that perturb cell states, which may enable repurposing of escitalopram and other drugs to limit cardiac remodeling through "off-target" pathways.

systems biology↗

bioRxiv2023

Pannexin 1 Channels Control Cardiomyocyte Metabolism and Neutrophil Recruitment During Non-Ischemic Heart Failure

Pannexin 1 (PANX1), a ubiquitously expressed ATP release membrane channel, has been shown to play a role in inflammation, blood pressure regulation, and myocardial infarction. However, a possible role of PANX1 in cardiomyocytes in the progression of heart failure has not yet been investigated. We generated a novel mouse line with constitutive deletion of PANX1 in cardiomyocytes (Panx1MyHC6). PANX1 deletion in cardiomyocytes had no effect on unstressed heart function but increased the glycolytic metabolism both in vivo and in vitro. In vitro, treatment of H9c2 cardiomyocytes with isoproterenol led to PANX1-dependent release of ATP and Yo-Pro-1 uptake, as assessed by pharmacological blockade with spironolactone and siRNA-mediated knock-down of PANX1. To investigate non-ischemic heart failure and the preceding cardiac hypertrophy we administered isoproterenol, and we demonstrate that Panx1MyHC6 mice were protected from systolic and diastolic left ventricle volume increases and cardiomyocyte hypertrophy. Moreover, we found that Panx1MyHC6 mice showed decreased isoproterenol-induced recruitment of immune cells (CD45+), particularly neutrophils (CD11b+, Ly6g+), to the myocardium. Together these data demonstrate that PANX1 deficiency in cardiomyocytes impacts glycolytic metabolism and protects against cardiac hypertrophy in non-ischemic heart failure at least in part by reducing immune cell recruitment. Our study implies PANX1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in heart failure patients.

physiology↗

bioRxiv2022

Dynamic map illuminates Hippo to cMyc module crosstalk driving cardiomyocyte proliferation

Cardiac diseases are characterized by the inability of adult mammalian hearts to overcome the loss of cardiomyocytes (CMs). Current knowledge in cardiac regeneration lacks a clear understanding of the molecular systems determining whether CMs will progress through the cell cycle to proliferate. Here, we developed a computational model of cardiac proliferation signaling that identifies key regulators and provides a systems-level understanding of the cardiomyocyte proliferation regulatory network. This model defines five regulatory networks (DNA replication, mitosis, cytokinesis, growth factor, hippo pathway) of cardiomyocyte proliferation, which integrates 72 nodes and 88 reactions. The model correctly predicts 72 of 76 (94.7%) independent experiments from the literature. Network analysis predicted key signaling regulators of DNA replication (e.g., AKT, CDC25A, Cyclin D/CDK4, E2F), mitosis (e.g., Cyclin B/CDK2, CDC25B/C, PLK1), and cytokinesis, whose functions varied depending on the environmental context. Regulators of DNA replication were found to be highly context-dependent, while regulators of mitosis and cytokinesis were context-independent. We also predicted that in response to the YAP-activating compound TT-10, the Hippo module crosstalks with the growth factor module via PI3K, cMyc, and FoxM1 to drive proliferation. This prediction was validated with inhibitor experiments in primary rat cardiomyocytes and further supported by re-analysis of published data on YAP-stimulated mRNA and open chromatin of Myc from mouse hearts. This study contributes a systems framework for understanding cardiomyocyte proliferation and identifies potential therapeutic regulators that induce cardiomyocyte proliferation.

systems biology↗

bioRxiv2022

Alteration of myocardial structure and function in RAF1associated Noonan syndrome: Insights from cardiac disease modeling based on patient-derived iPSCs

Noonan syndrome (NS), the most common among the RASopathies, is caused by germline variants in genes encoding components of the RAS-MAPK pathway. Distinct variants, including the recurrent Ser257Leu substitution in RAF1, are associated with severe hypertrophic cardiomyopathy (HCM). Here, we investigated the elusive mechanistic link between NS-associated RAF1S257L and HCM using three-dimensional cardiac bodies and bioartificial cardiac tissues generated from patient-derived induced pluripotent stem cells (iPSCs) harboring the pathogenic RAF1 c.770C>T missense change. We characterize the molecular, structural and functional consequences of aberrant RAF1 -associated signaling on the cardiac models. Ultrastructural assessment of the sarcomere revealed a shortening of the I-bands along the Z disc area in both iPSC-derived RAF1S257L cardiomyocytes, and myocardial tissue biopsies. The disease phenotype was partly reverted by using both MEK inhibition, and a gene-corrected isogenic RAF1L257S cell line. Collectively, our findings uncovered a direct link between a RASopathy gene variant and the abnormal sarcomere structure resulting in a cardiac dysfunction that remarkably recapitulates the human disease. These insights represent a basis to develop future targeted therapeutic approaches.

cell biology↗

bioRxiv2020

Ablation of endogenously cycling adult cardiomyocytes worsens myocardial function after injury

RationaleEndogenously cycling adult cardiomyocytes (CMs) increase after myocardial infarction (MI) but remain scare, and are generally thought not to contribute to myocardial function. However, this broadly held assumption has not been tested, mainly because of the lack of transgenic reporters that restrict Cre expression to adult CMs that reenter the cell cycle. ObjectiveWe created and validated a new transgenic mouse, MHC-MerDreMer-Ki67p-RoxedCre::Rox-Lox-tdTomato-eGFP (denoted DKRC) that restricts Cre expression to cycling adult CMs and uniquely integrates spatial and temporal adult CM cycling events based on the DNA specificities of orthologous Dre- and Cre recombinases. We then created mice that expressed an inducible Diphtheria toxin (DTA), DKRC::DTA mice, in adult cycling CMs and examined the effects of ablating these endogenously cycling CMs on myocardial function after Ischemic-Reperfusion (I/R) MI. Methods and ResultsA tandem DKRC transgene was designed, validated in cultured cells, and used to make transgenic mice. The DKRC transgene integrated between MYH6 and MYH7 and did not disrupt expression of the surrounding genes. Compared to controls, DKRC::RLTG mice treated with Tamoxifen expressed tdTomato+ in CMs with rare Bromodeoxyuridine (BrdU)+, eGFP+ CMs, consistent with reentry of the cell cycle. We then pre- treated DKRC::RLTG mice with Tamoxifen to activate the reporter before sham or reperfusion (I/R) myocardial infarction (MI) surgeries. Compared to Sham surgery, the I/R MI group had increased single and paired eGFP+ CMs predominantly in the border zones (5.8 {+/-} 0.5 vs. 3.3 {+/-} 0.3 CMs per ten-micron section, N = 8 mice, n = 16 sections per mouse), indicative of cycled CMs. The single to paired eGFP+ CM ratio was [~]9 to 1 (5.2 {+/-} 0.4 single vs. 0.6 {+/-} 0.2 paired CMs) in the I/R MI group after MI, suggesting that cycling CMs were more likely to undergo polyploidy than replication. The ablation of endogenously cycling adult CMs in DKRC::DTA mice caused progressive worsening left ventricular chamber size and function after I/R MI, compared to controls. ConclusionsAlthough scarce, endogenously cycling adult CMs contribute to myocardial function after injury, suggesting that these cells may be physiologically relevant.

cell biology↗

bioRxiv2019

Suppression of store-operated calcium entry causes dilated cardiomyopathy of the Drosophila heart

Store-operated Ca2+ entry (SOCE) is an essential Ca2+ signaling and homeostatic mechanism present in nearly all animal cells. SOCE refers to influx of Ca2+ into cells that is activated by depletion of endoplasmic or sarcoplasmic reticulum stores (ER/SR) Ca2+ stores. In the SOCE pathway, STIM proteins function as Ca2+ sensors in the ER, and upon ER Ca2+ store depletion STIM rearranges to ER-plasma membrane junctions where it activates Orai Ca2+ influx channels. Multiple studies have implicated STIM and Orai mediated SOCE in the pathogenesis of cardiac hypertrophy. Importantly however, the functional roles of SOCE in normal heart physiology have not been well defined. We have addressed this in Drosophila melanogaster, a powerful animal model of cardiac development and physiology. We show that heart specific suppression of Drosophila Stim and Orai resulted in reduced contractility consistent with dilated cardiomyopathy, characterized by increased end diastolic and end systolic dimensions and decreased fractional shortening. Reduced contractility was apparent in larval hearts and became more pronounced in adults. Myofibers were disorganized and more widely spaced in larval and adult hearts with Stim and Orai RNAi as compared to controls, possibly reflecting decompensation or upregulated stress response signaling due to altered Ca2+ homeostasis. Lastly, we show that reduced heart function significantly affected animal health and viability, as animals with heart specific Stim and Orai suppression exhibited significant delays in post-embryonic development and adults died significantly earlier than controls. Collectively, our results demonstrate that SOCE is essential for normal heart physiology and establish Drosophila as an important model for delineation of functional SOCE roles in cardiomyocytes.

physiology↗